Industrifonden appoints new Investment Director/Head of Business Unit Life Science
Industrifonden has appointed Nina Rawal as new Investment Director/Head of Business Unit Life Science. She replaces Lennart Hansson who transitions into a role of Senior Advisor.
“Nina Rawal’s extensive background, expertise and strong commitment make her perfectly suited to take over the reins and to continue developing our engagement within Life Science. At the same time, I am delighted that we can keep Lennart Hansson as part of the team. Through his important contribution, Industrifonden is now one of the leading Life Science investors in the Nordic region. Lennart will now have the opportunity to focus on a set of strategic projects that will contribute to the long-term success of the fund,” says Anders Slettengren, CEO of Industrifonden.
Nina Rawal joined Industrifonden in 2013 as Investment Manager, having come from Gambro where she was Vice President of Strategy and Ventures. She previously held positions at The Boston Consulting Group in Stockholm and New York, Swecare Foundation and Médecins Sans Frontières. Nina has a Master’s degree in Biomedicine and a PhD in Molecular Neurobiology, both from Karolinska Institutet.
“I am proud and excited to take over the leadership of our Life Science operations. We are well positioned to further develop Industrifonden’s role as a major catalyst in the Nordic Life Science industry,” says Nina Rawal, incoming Investment Director/Head of Business Unit Life Science at Industrifonden.
Nina Rawal and Lennart Hansson will take up their new positions on April 1, 2016. Nina will simultaneously join Industrifonden’s Executive Management Team.
“After eight years as Investment Director, I am now looking forward to devoting more time to select strategic projects that are close to my heart, but which I have not been able to work on previously due to time constraints,” says Lennart Hansson, incoming Senior Advisor.
Industrifonden is one of the Nordic region’s most active investors in the Life Science area, with a focus on pharmaceuticals, medical technology and e-health. The fund’s current holdings include BONESUPPORT, Pharmalink and AMRA.
For further information, please contact
Anders Slettengren, CEO of Industrifonden
Tel: +46 (0)72-589 89 00, E-mail: email@example.com
Nina Rawal, incoming Investment Director/Head of Business Unit Life Science
Tel: +46 (0)70-515 01 89, E-mail: firstname.lastname@example.org
Industrifonden is a Swedish venture capital investor focusing on early stage tech and life science companies with international potential. We are an active partner to companies with groundbreaking ideas and capacity to grow. Founded in 1979, Industrifonden is an evergreen fund with SEK 4 billion in assets. Read more: Website, Twitter, LinkedIn.